Futura Medical plc (FUM) 2019年年度报告「LSE」.pdf

《Futura Medical plc (FUM) 2019年年度报告「LSE」.pdf》由会员分享，可在线阅读，更多相关《Futura Medical plc (FUM) 2019年年度报告「LSE」.pdf（84页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report and Accounts 2019Futura Medical plc Annual Report and Accounts 2019Futura Medical Welcome to the Futura Medical Annual Report 2019Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on our proprietary,transdermal technology DermaSys.These prod

2、ucts are optimised for clinical efficacy,safety,mode of administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate.Current therapeutic areas are sexual health and pain relief.Development and commercialisation strategies are designed t

3、o maximise product differentiation and value creation whilst seeking to minimise clinical and regulatory risk.WHAT WE DOJAMES BARDER Chief Executive Our purpose is to enhance our patients and consumers quality of life to enable them to live their lives to the full.STRATEGIC REPORTSTRATEGIC REPORT12A

4、dvanced proprietary technology DermaSysWe are exploiting the potential of our transdermal technology DermaSys to innovate and develop topical treatments offering a fast onset of action and low systemic side effects.Our long-term strategy is to expand the product pipeline based on DermaSys.We are cur

5、rently exploring opportunities with cannabidiol in CBD100.Our products are underpinned by strong IP,usually specific to each product.Clinical development of treatments for unmet needsOur focus is on differentiated products,addressing areas of two large markets,sexual health and pain,seeking to solve

6、 unmet needs that will help improve patients and consumers lives.5Experienced management teamThe management team has significant experience in researching and developing innovative products for the global consumer healthcare and prescription markets,with extensive development and regulatory expertis